F Perrodeau1, M Pillot-Debelleix2, J Vergniol3, F Lemonnier4, M-C Receveur5, P Trimoulet6, I Raymond7, G Le Port8, S Gromb-Monnoyeur9. 1. UCSA de la Maison d'arrêt Bordeaux-Gradignan, BP 109, 33173 Gradignan cedex, France. Electronic address: florenceperrodeau@gmail.com. 2. UCSA de la Maison d'arrêt Bordeaux-Gradignan, BP 109, 33173 Gradignan cedex, France. Electronic address: marie.pillot@chu-bordeaux.fr. 3. Service d'hépato-gastro-entérologie et d'oncologie, groupe hospitalier Sud, groupe hospitalier Haut-Lévêque, 1, avenue Magellan, 33600 Pessac, France. Electronic address: julien.vergniol@chu-bordeaux.fr. 4. UCSA de la Maison d'arrêt Bordeaux-Gradignan, BP 109, 33173 Gradignan cedex, France. Electronic address: fabienne.lemonnier@chu-bordeaux.fr. 5. Unité des maladies tropicales et du voyageur, service des maladies infectieuses et tropicales, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. Electronic address: marie-catherine.receveur@chu-bordeaux.fr. 6. Laboratoire de microbiologie fondamentale et pathogénicité, UMR-CNRS 5234, bâtiment 2A, 3(e) étage, 146, rue Léo-Saignat, 33076 Bordeaux cedex, France. Electronic address: pascale.trimoulet@chu-bordeaux.fr. 7. Service de médecine interne et des maladies infectieuses (Sud), groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. Electronic address: isabelle.raymond@chu-bordeaux.fr. 8. UCSA de la Maison d'arrêt Bordeaux-Gradignan, BP 109, 33173 Gradignan cedex, France. Electronic address: gildas.le-port@chu-bordeaux.fr. 9. Unité de médecine légale, institut médico-judiciaire, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. Electronic address: sophie.gromb@chu-bordeaux.fr.
Abstract
OBJECTIVE: We aimed to establish the current status of hepatitis B virus (HBV) vaccination in prison. METHODS: We carried out two evaluations within a 1-year interval with inmates incarcerated for 6 to 12 months. A monitoring process was introduced in-between the two evaluations. RESULTS: We included 231 inmates. Overall, 42.9% were immunized because of a previous vaccination and 14.3% because of a previous exposure. Inmates born in an area of medium or high endemicity for HBV were significantly more exposed to HBV. The proportion of non-immunized inmates was 42.8% at the time of incarceration and 27.5% after 6 to 12 months. Vaccination coverage with two doses, after 6 to 12 months, was 63% among patients who were initially non-immunized. CONCLUSION: The recently developed accelerated vaccination schedule should help improve HBV vaccination coverage.
OBJECTIVE: We aimed to establish the current status of hepatitis B virus (HBV) vaccination in prison. METHODS: We carried out two evaluations within a 1-year interval with inmates incarcerated for 6 to 12 months. A monitoring process was introduced in-between the two evaluations. RESULTS: We included 231 inmates. Overall, 42.9% were immunized because of a previous vaccination and 14.3% because of a previous exposure. Inmates born in an area of medium or high endemicity for HBV were significantly more exposed to HBV. The proportion of non-immunized inmates was 42.8% at the time of incarceration and 27.5% after 6 to 12 months. Vaccination coverage with two doses, after 6 to 12 months, was 63% among patients who were initially non-immunized. CONCLUSION: The recently developed accelerated vaccination schedule should help improve HBV vaccination coverage.
Authors: Nancy Vicente-Alcalde; Jose Tuells; Cecilia M Egoavil; Esther Ruescas-Escolano; Cesare Altavilla; Pablo Caballero Journal: Int J Environ Res Public Health Date: 2020-10-31 Impact factor: 3.390
Authors: Nancy Vicente-Alcalde; Esther Ruescas-Escolano; Zitta Barrella Harboe; José Tuells Journal: Int J Environ Res Public Health Date: 2020-10-19 Impact factor: 3.390